Figure 5.
(a) Effect of olaparib on AKR1C3-mediated intracellular daunorubicin (Daun) metabolism in HCT116 cells. Statistical analysis was performed with end-point data, using one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc test (* p ≤ 0.05, *** p ≤ and **** p ≤ 0.0001, compared to AKR1C3 control). (b) IC50 of AKR1C3 inhibition in HCT116 cells exposed to olaparib (1–50 µM). Data are expressed as the mean ± SD from three independent assays.